Fetal Diagnosis and Therapy
Abstract
Introduction: The purpose of this study was to evaluate the within-pair difference in retinopathy of prematurity (ROP) between donors and recipients with twin-to-twin transfusion syndrome (TTTS) and to identify risk factors for ROP development.
Methods: This retrospective cohort study included 147 TTTS twin pairs managed between 2002-2022 and eligible for ROP screening. Primary outcomes were any stage ROP and severe ROP. Secondary outcomes were hemoglobin at birth, red blood cell transfusions, mechanical ventilation days, postnatal steroids and neonatal morbidity.
Results: Rates of any stage ROP (23% vs. 14%) and severe ROP (8% vs. 3%) were significantly higher in donors compared to recipients. Donors received a higher number of blood transfusions (1 (±1.9) vs. 0.7 (±1.5)). Five factors were univariately associated with any stage ROP: donor status (OR 1.9; 95% CI 1.3–2.9), lower GA at birth (OR 1.7; 95% CI 1.4–2.1), small for GA (OR 2.1; 95% CI 1.3–3.5), mechanical ventilation days (OR 1.1; 95% CI 1.1–1.2) and blood transfusions in phase 1 (OR 2.3; 95% CI 1.2–4.3). Three factors were independently associated with any stage ROP: donor status (OR 1.8; 95% CI 1.1–2.9), lower GA at birth (OR 1.6; 95% CI 1.2–2.1) and mechanical ventilation days (OR 1.1, 95% CI 1.0–1.1). Donor status was univariately associated with severe ROP (OR 2.3, 95% CI 1.1–5.0).
Conclusion: Any stage ROP and severe ROP are detected twice as frequently in donors compared to recipients. Increased awareness for ROP is needed in donors, especially those with lower GA at birth and longer duration of mechanical ventilation.
The Author(s). Published by S. Karger AG, Basel
Article / Publication Details
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Comments (0)